The term Acute on chronic liver failure (ACLF) describes a clinical entity characterized by an acute and rapid deterioration of liver function in a patient with previously well-compensated liver disease owing to the effects of a precipitating event. In this condition two insults act simultaneously, one being the preexisting liver injury (chronic liver disease) and the other acute injury which is responsible for the acute decompensation. HEV being a major factor responsible for this clinical entity and has a very high mortality rate. Ribavirin being a safe drug and has been shown to inhibit the replication of HEV, can be an important drug in the treatment of these patients. Therefore the present study is designed to study the impact of Ribavirin in reducing the mortality due to HEV related ACLF.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
40
AII India Institute of Medical Sciences
Delhi, National Capital Territory of Delhi, India
RECRUITINGAll India Institute of Medical Sciences
Delhi, National Capital Territory of Delhi, India
RECRUITINGImprovement in survival
Time frame: 4 weeks and 12 moths
Child Score
Change in Child Score will be evaluated at every 4 week interval
Time frame: 4 weeks and 12 months
Viremia
Change in viral load
Time frame: 4 weeks, 3 months
Variceal bleeding
Variceal bleeding will be assessed every 4 weeks
Time frame: 4 weeks and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.